Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions
Metastatic Esophageal AdenocarcinomaAdvanced Esophageal AdenocarcinomaMetastatic Gastric AdenocarcinomaAdvanced Gastric Adenocarcinoma
Interventions
DRUG

Ivonescimab

Ivonescimab 20 mg/kg by intravenous (IV) infusion once every 2 weeks until disease progression.

DRUG

FOLFOX regimen

Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour continuous IV infusion, every two weeks for 8 cycles followed by 5FU as maintenance therapy until disease progression.

DRUG

Irinotecan

180 mg/ m2 IV over 90 min infusion every two weeks for a minimum of 4 cycles

DRUG

Paclitaxel

80 mg/m2 IV at D1, D8 and D15, every four weeks (D1=D28)

Trial Locations (2)

Unknown

Institut Paoli Calmettes, Marseille

Institut de Cancerologie de l'Ouest - Site René Gauducheau, Saint-Herblain

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Summit Therapeutics

INDUSTRY

lead

UNICANCER

OTHER

NCT06846346 - Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma | Biotech Hunter | Biotech Hunter